Recent News

• 12.09.2025 - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 11.21.2025 - Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
• 11.19.2025 - Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
• 11.18.2025 - Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
• 11.10.2025 - Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
• 11.06.2025 - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 11.06.2025 - Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.04.2025 - Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
• 11.03.2025 - Esperion to Participate in Jefferies Global Healthcare Conference - London
• 10.28.2025 - Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

Recent Filings

• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 3 Initial statement of beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - 8-K Current report
• 11.04.2025 - EX-99.1 EX-99.1